Back to top
more

Anthera Pharmaceuticals (ANTH)

(Delayed Data from OTC)

$0.00 USD

0.00
NA

0.00 (0.00%)

Updated Mar 14, 2024 10:46 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Implied Volatility Surging for Anthera Pharmaceuticals (ANTH) Stock Options

Surging implied volatility makes Anthera Pharmaceuticals (ANTH) stock lucrative to the option traders.

    Shire (SHPG) to Report Q4 Earnings: What's in the Cards?

    Shire (SHPG) will report its Q4 results on Feb 14, 2018.

      Will Ocaliva Sales Dampen Intercept's (ICPT) Q4 Earnings?

      The recent weakness in lead drug Ocaliva sales due to safety issues may mar Intercept's (ICPT) performance in the fourth quarter.

        Zoetis (ZTS) Warming Up to Q4 Earnings: What's in Store?

        Zoetis (ZTS) is working on returning value to shareholders in the form of share buybacks and dividends.

          Spectrum Pharma's Rolontis Positive in Pivotal Cancer Study

          Spectrum Pharmaceuticals' (SPPI) Rolontis meets primary endpoint in a phase III study for management of neutropenia in early stage breast cancer.

            Will Regeneron (REGN) Disappoint Investors in Q4 Earnings?

            With a mixed track record, we expect investor focus on Regeneron's (REGN) Eylea sales and uptake of Dupixent when it reports Q4 results.

              Keryx (KERX) Warming Up to Q4 Earnings: What's in Store?

              Keryx (KERX) will provide updates on lead drug Auryxia when it reports Q4 results on Feb 7.

                Is a Beat in Store for Alexion (ALXN) This Earnings Season?

                Alexion's (ALXN) Q4 results are likely to driven by Soliris' performance.

                  Will Gilead (GILD) Disappoint Investors in Q4 Earnings?

                  Biotech bigwig Gilead Sciences (GILD) Q4 results are expected to be adversely impacted by the decline in HCV market share.

                    Will Bristol-Myers' (BMY) Q4 Earnings Exceed Expectations?

                    Bristol-Myers' (BMY) Opdivo is likely to play an instrumental role in driving fourth-quarter 2017 results.

                      What's in the Cards for GW Pharma (GWPH) in Q1 Earnings?

                      GW Pharma (GWPH) will report fiscal first-quarter results next week. Investors focus is expected to be on the Epidiolex commercialization plan.

                        What's in Store for Cardinal Health (CAH) in Q2 Earnings?

                        Pricing pressure in generics portfolio is likely to mar Cardinal Health's (CAH) top line in Q2.

                          Can Molecular Diagnostics Arm Up Hologic (HOLX) Q1 Earnings?

                          Molecular Diagnostics unit's stellar performance in the first quarter of 2018 is likely to drive Hologic (HOLX) in Q1.

                            Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?

                            Vertex Pharmaceuticals (VRTX) will report its Q4 results on Jan 31, 2018.

                              Will Higher System Sales Drive Cerner's (CERN) Q4 Earnings?

                              Cerner (CERN) expects solid Q4 revenues on a surge in bookings. Stiff competition remains a concern.

                                The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Bio-Techne, Exelixis, Paratek and Bioverativ

                                The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Bio-Techne, Exelixis, Paratek and Bioverativ

                                  Anthera's Sollpura Strong on Positive Futility in Phase III

                                  Anthera (ANTH) posts positive results from the second interim futility analysis of Sollpura for EPI. Top-line data from the study is expected in the first quarter of 2018.

                                    Anthera's Blisibimod Positive in Phase II Extension Study

                                    Anthera's (ANTH) blisibimod passes test in an extended phase II study to prove efficacy for IgA nephropathy treatment. The study also shows a trend toward preservation of renal function.

                                      Debasmita Banerjee headshot

                                      Axovant Sciences (AXON) Shows Strength: Stock Jumps 9.2%

                                      Axovant Sciences Ltd. (AXON) shares rose a little above 9% in the last trading session.

                                        ANTH's (ANTH) Blisibimod Completes Dosing in Phase III Study

                                        Anthera Pharmaceuticals, Inc. (ANTH) recently announced the completion of dosing in a phase II study, BRIGHT-SC. The study evaluated key pipeline candidate blisibimod for treatment of patients with IgA nephropathy (IgAN).

                                          Should You Get Rid of Aimmune Therapeutics (AIMT) Now?

                                          Aimmune Therapeutics (AIMT) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.

                                            BioTelemetry (BEAT) Shows Strength: Stock Moves 8.8% Higher

                                            BioTelemetry, Inc. (BEAT) shares rose almost 9% in the last trading session.

                                              Cellect Biotechnology (APOP) Jumps: Stock Moves 10.5% Higher

                                              Cellect Biotechnology Ltd. (APOP) shares rose over 10% in the last trading session.

                                                Bill Ackman Apologizes for Valeant Investment Error

                                                In a letter addressed to shareholders, Bill Ackman, chairman of Perishing Square Holdings, Ltd stated that investing in Valeant Pharmaceuticals (VRX) was a big mistake on his part.

                                                  Cara Therapeutics (CARA) Shows Strength: Stock Up 5.2%

                                                  Cara Therapeutics, Inc. (CARA) shares rose above 5% in the last trading session.